Table 4.
The incremental comparison of ICERs for different medication scenarios
| Relative effectiveness | 1. EMR + symptoms vs 0. No screening |
5. Echocardiography vs 1. EMR + symptoms |
|---|---|---|
| Men (%) | ||
| 0 | €6115 | €29,100 |
| 10 | €5573 | €27,552 |
| 20 | €5067 | €26,157 |
| 30 | €4591 | €24,895 |
| 40 | €4140 | €23,749 |
| 50 | €3709 | €22,705 |
| 60 | €3293 | €21,753 |
| 70 | €2890 | €20,880 |
| 80 | €2494 | €20,079 |
| 90 | €2102 | €19,341 |
| 100 | €1711 | €18,660 |
| Women (%) | ||
| 0 | €6318 | €39,326 |
| 10 | €5888 | €38,122 |
| 20 | €5496 | €37,015 |
| 30 | €5137 | €35,998 |
| 40 | €4807 | €35,067 |
| 50 | €4502 | €34,216 |
| 60 | €4219 | €33,442 |
| 70 | €3995 | €32,741 |
| 80 | €3706 | €32,110 |
| 90 | €3471 | €31,547 |
| 100 | €3248 | €31,049 |
EMR Electronic Medical Record, PE physical examination ICER incremental cost-effectiveness ratio. Relative effectiveness represents HFPEF medication effectiveness as a percentage of the effectiveness in HFREF. For each strategy the incremental life-years, QALYs and costs are compared to the current optimal strategy and the ICER was calculated. Strategies 2, 3, and 4 were dominated by strategy 5